Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study for Anti-TNFα Antibody for Canine Inflammatory Bowel Disease

Rhea-AI Summary

Kindred Biosciences (NASDAQ: KIN) reported positive results from a pilot study assessing its anti-TNFα antibody for treating canine inflammatory bowel disease (IBD). Conducted with 10 dogs, the randomized, placebo-controlled trial found that 75% of treated dogs achieved significant remission compared to only 17% in the placebo group. The treatment demonstrated early and lasting effects, indicating strong potential for this therapeutic in addressing IBD, a common condition in dogs. CEO Richard Chin emphasized the unmet need in canine gastrointestinal diseases and the promising outcomes of the study.

Positive

• 75% of treated dogs achieved ≥ 75% reduction in CIBDAI score.
• The anti-TNFα antibody showed early-onset and durable treatment effects.
• Demonstrates potential to address an important unmet need in canine health.

Negative

• None.

SAN FRANCISCO, Dec. 21, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from the pilot field effectiveness study of its monoclonal antibody against tumour necrosis factor alpha (anti-TNFα antibody) for canine inflammatory bowel disease (IBD).

The study was a randomized, blinded, placebo-controlled pilot effectiveness study that enrolled 10 dogs diagnosed with IBD to assess the efficacy and safety of KindredBio's anti-TNFα antibody over a 4-week treatment period. The primary effectiveness variable for this exploratory study was reduction in Canine Inflammatory Bowel Disease Activity Index (CIBDAI) score, which was assessed at Screening and Days 0, 7, 14, 21 and 28. Complete remission, defined as ≥ 75% reduction in average post-dose CIBDAI score from baseline, was achieved in 75% of the anti-TNFα group compared to 17% in the placebo group. The treatment effect was early-onset and durable. At Day 7, the first post-dose visit, 75% of the anti-TNFα treated dogs showed ≥ 75% reduction of CIBDAI score from baseline, compared to 17% in the placebo group. Furthermore, 50% of the anti-TNFα treated dogs achieved and maintained 100% reduction of CIBDAI score from baseline throughout all post-dose visits, whereas none in the placebo group achieved the same result.

"We are pleased to have observed a positive signal from this study, which marks the latest in a string of positive study results for our biologics candidates," said KindredBio's Chief Executive Officer, Richard Chin, M.D. "Gastrointestinal disease, which is often immune-mediated, is one of the most common diseases in dogs, and is an important unmet need, because existing treatments are often poorly effective and can have safety liabilities. Given the rapid and pronounced effect of this product candidate, we believe that it could become a very successful therapeutic."

The majority of canine IBD cases involve chronic states of diarrhea, vomiting, gastroenteritis, inappetence, and other symptoms. For certain dog breeds, the prevalence of diarrhea exceeds 5%.

About Kindred Biosciences

Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.

For more information, visit: www.kindredbio.com

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our expectations about the trials, regulatory approval, manufacturing, distribution and commercialization of our current and future product candidates, and statements regarding our anticipated revenues, expenses, margins, profits and use of cash.

These forward-looking statements are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; the absence of significant revenue from our products and our product candidates for the foreseeable future; the likelihood that our revenue will vary from quarter to quarter; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our products and our lead product candidates which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our products and our product candidates and the potential inability of these manufacturers to deliver a sufficient  amount of supplies on a timely basis; the uncertain effect of the COVID-19 pandemic on our business, results of operations and financial condition; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to enter into satisfactory agreements with third-party licensees of our biologic products or to develop a satisfactory sales organization for our equine small molecule products; our significant costs of operating as a public company; potential cyber-attacks on our information technology systems or on our third-party providers' information technology systems, which could disrupt our operations; our potential inability to repay the secured indebtedness that we have incurred from third-party lenders, and the restrictions on our business activities that are contained in our loan agreement with these lenders; the risk that our 2020 strategic realignment and restructuring plans will result in unanticipated costs or revenue shortfalls; uncertainty about the amount of royalties that we will receive from the sale of Mirataz® to Dechra Pharmaceuticals PLC; the risk that the revenue from our delivery of services or products under any contract may be less than we anticipate if the other party to the contract exercises its right to terminate the contract prior to the completion of the contract; our potential inability to obtain and maintain patent protection and other intellectual property protection for our products and our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management. 

For a further description of these risks and other risks that we face, please see the risk factors described in our filings with the U.S. Securities and Exchange Commission (the SEC), including the risk factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K and any subsequent updates that may be contained in our Quarterly Reports on Form 10-Q filed with the SEC. As a result of the risks described above and in our filings with the SEC, actual results may differ materially from those indicated by the forward-looking statements made in this press release. Forward-looking statements contained in this press release speak only as of the date of this press release and we undertake no obligation to update or revise these statements, except as may be required by law.

The results stated in this press release have not been reviewed by the Food and Drug Administration or the United States Department of Agriculture Center for Veterinary Biologics, as applicable.

Contacts

For investor inquiries: 
Katja Buhrer
Katja.buhrer@kindredbio.com 
(917) 969-3438

View original content to download multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-announces-positive-results-from-pilot-field-effectiveness-study-for-anti-tnf-antibody-for-canine-inflammatory-bowel-disease-301196541.html

SOURCE Kindred Biosciences, Inc.

FAQ

What were the results of Kindred Biosciences' pilot study for canine IBD?

In a pilot study, 75% of dogs treated with Kindred Biosciences' anti-TNFα antibody achieved significant remission from IBD, compared to 17% in the placebo group.

When was the press release about Kindred Biosciences' study published?

The press release was published on December 21, 2020.

What is the significance of the positive results for KIN stock?

The positive results from the study indicate potential market success for KIN's anti-TNFα antibody, which could boost investor confidence and stock performance.

What is the primary focus of Kindred Biosciences?

Kindred Biosciences focuses on developing biopharmaceuticals to improve the health and lives of pets.